echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hutchison Pharmaceuticals and Epizyme cooperate to develop and commercialize TAZVERIK in Greater China

    Hutchison Pharmaceuticals and Epizyme cooperate to develop and commercialize TAZVERIK in Greater China

    • Last Update: 2021-08-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On August 9, Hutchison Pharmaceuticals and Epizyme announced their cooperation to conduct research, development, production and commercialization of TAZVERIK® in Greater China (including China, Hong Kong, Macau and Taiwan)


    TAZVERIK® is an EZH2 methyltransferase inhibitor developed by Epizyme and has been approved by the US FDA for the treatment of certain epithelioid sarcoma (ES) patients and certain follicular lymphoma (FL) patients


    According to the terms of the agreement, Hutchison Pharma will be responsible for the development and commercialization of TAZVERIK® in Greater China


    Hutchison Medical plans to be responsible for the development and approval of TAZVERIK® for the treatment of various blood and solid tumors in its region, including epithelioid sarcoma, follicular lymphoma and diffuse large B-cell lymphoma (DLBCL)


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.